Apolipoprotein A1 level in plasma of patients with diabetes and diabetic patients with COVID-19 as a possible marker of disease

• Дата: 2021
• Автори: Tronko, M.D., Cherviakova, S.A., Pushkarev, V.V., Belchina, Y.B., Kovzun, O.I., Pushkarev, V.M., Sokolova, L.K.
• Формат: Стаття
• Мова: English
• Опубліковано: Видавничий дім "Академперіодика" НАН України 2021
• Назва видання: Доповіді НАН України
• Теми: Біохімія
• Онлайн доступ: http://dspace.nbuv.gov.ua/handle/123456789/180577
• Назва журналу: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Цитувати: Apolipoprotein A1 level in plasma of patients with diabetes and diabetic patients with COVID-19 as a possible marker of disease / M.D. Tronko, S.A. Cherviakova, V.V. Pushkarev, Y.B. Belchina, O.I. Kovzun, V.M. Pushkarev, L.K. Sokolova // Доповіді Національної академії наук України. — 2021. — № 4. — С. 110-113. — Бібліогр.: 10 назв. — англ.

Increased levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (ApoA1) in plasma is associated with a reduced risk of developing cardiovascular diseases (CVD). In addition to its potential cardioprotective function, HDL and ApoA1, the main HDL apolipoprotein, also have antidiabetic properties. The aim of the study was to determine the level of ApoA1 in the blood of patients (n = 81) with type 2 diabetes mellitus and COVID-19. ApoA1 was determined by enzyme-linked immunosorbent assay (ELISA) (Elabscience, USA). The measurements were performed at an optical density of 450 nm. We showed that the level of ApoA1 in the blood of patients with type 2 diabetes and especially with COVID-19 was significantly lower than in the blood of healthy people. Blood ApoA1 levels did not show a further decrease in patients with both COVID-19 and diabetes compared with patients with COVID-19 without diabetes. Thus, the level of ApoA1 may be one of the promising markers of severe COVID-19.